Drug Trial Radar · NCT06586866
JK-1201I in Triple Negative Breast Cancer Patients with Brain Metastases
Last checked: Nov 20, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
25
Planned (sponsor's estimate)
Start
Sep 26, 2024
Primary completion
May 26, 2026
Study completion Oct 26, 2026
Sponsor
- Lead sponsor
- JenKem Technology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study was designed to evaluate the safety, efficacy and pharmacokinetics of JK-1201I in triple negative breast cancer patients with brain metastases.
Conditions
- Triple Negative Breast Cancer (TNBC)
- Brain Metastasases
Interventions
JK-1201IDrug
JK-1201I will be administered as an IV infusion at dose of 125mg/m2 on Day 1 of each 14-day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival (PFS) according to RECIST 1.1 and RANO-BMTime frame: Up to approximately 12 months.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.